Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649180 · ClinicalTrials.gov registry record · Phase 2
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
A Phase 2 study, sponsored by PrECOG.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01649180 is a Phase 2 study that was terminated before completion, run by PrECOG. The registered enrollment target is 3 participants.
The verdict
NCT01649180, a Phase 2 study, was terminated before completion, sponsored by PrECOG.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to see how well the study drug, axitinib, helps control renal (kidney) cancer that has come back (recurrent) or spread (metastatic). Patients must have already been treated as a participant in a clinical trial with sunitinib, sorafenib, pazopanib or placebo (sugar pill) after their initial surgery. This study will examine the effect of adjuvant tyrosine kinase inhibition (TKI) therapy (sorafenib, sunitinib or pazopanib) on subsequent exposure to TKI with axitinib in the first-line recurrent or metastatic setting.
Interventions
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01649180
The ClinicalTrials.gov registry entry for NCT01649180 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axitinib is the first listed.
NCT01649180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01649180 about?
NCT01649180 is a clinical study titled "NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma". The purpose of this study is to see how well the study drug, axitinib, helps control renal (kidney) cancer that has come back (recurrent) or spread (metastatic). Patients must have already been treated as a participant in a clinical trial with sunitinib, sorafenib, pazopanib or placebo (sugar pill) ...
What is the current status of trial NCT01649180?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01649180?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT01649180?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.